

## REMARKS

Upon entry of the amendments made herein, claims 50-79 are pending in the application. Claims 1-49 have been cancelled without prejudice or disclaimer. Claims 50-79 have been added. Support for the additional claims can be found in Tables 1-3 of the specification and in claims 1-49 as originally filed. In an attempt to expedite prosecution, Applicants have drawn claims 50-104 toward the compositions 6, 7 and 11 listed in Tables 1-3 of the specification, which the Examiner deemed as allowable. (See, Office Action at page 4).

No new matter has been added.

### Rejections under 35 U.S.C. 112, Second Paragraph

Claims 48-49 were rejected under 35 U.S.C. 112, second paragraph for being indefinite. Claims 48-49 have been cancelled, thus this rejection is moot and should be withdrawn.

### Rejections under 35 U.S.C. 103

Claims 1-21, 23-43 and 45-49 are rejected under 35 U.S.C 103(a) as being unpatentable over the combined teachings of U.S. Patent No. 4,557,935 (“af Ekenstam”) and WO/8703779 (“the ‘779 publication”) in view of U.S. Patent No. 4,534,945 (“Hopkins”), U.S. Patent No. 5,078,672 (“Dougherty”), U.S. Patent No. 5,693,318 (“Burke”) and S. Block, Disinfection, Sterilization and Preservation, Fourth Edition (1991) (“Block”). Applicants traverse this rejection with respect to the claims as amended herein.


Claims 1-21, 23-43 and 45-49 have been cancelled herein, and with respect to new claims 50-104, Applicants submit that they are drawn toward compositions 6, 7 and 11 listed in Tables 1-3 of the specification, which the Examiner acknowledges are non-obvious. In view of new claims, Applicants request reconsideration and withdrawal of the rejection.

Claims 1-49 are rejected under 35 U.S.C 103(a) as being unpatentable over af Ekenstam and the ‘779 publication in view of Hopkins, Dougherty, Burke, Block and Derwent abstract 1999-541010 (“Derwent”). The teachings of all the references except for Derwent are discussed above. The Examiner indicates that Derwent teaches that hydrogen peroxide, salicylic acid and glycerol are known to be used together for dermatological purposes. (See, Office Action at page 11). Applicants traverse this rejection with respect to the claims as amended herein.

**Lindahl et al.**  
**USSN: 09/891,256**

Claims 1-21, 23-43 and 45-49 have been cancelled herein, and with respect to new claims 50-104, Applicants submit that they are drawn toward compositions 6, 7 and 11 listed in Tables 1-3 of the specification, which the Examiner acknowledges are non-obvious. In view of new claims, Applicants request reconsideration and withdrawal of the rejection.

On the basis of the foregoing amendment and remarks, Applicants respectfully submit that the pending claims are in condition for allowance and a Notice of Allowance for the pending claims is respectfully requested. If there are any questions regarding this application that can be handled in a phone conference with Applicants' Attorneys, the Examiner is encouraged to contact the undersigned at the telephone number provided below.



---

David E. Johnson, Reg. 41,874  
Erica Carlson, Reg. No. 58,032  
Attorneys for Applicant  
MINTZ, LEVIN, COHN, FERRIS  
GLOVSKY AND POPEO, P.C.  
One Financial Center  
Boston, MA 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241  
**Customer No. 30623**

Dated: September 8, 2009

4707428v.1